September's Clovertex Target of the Month is GPR61 following Pfizer's recent publication concerning...
This January 2024, we're spotlighting Bruton's tyrosine kinase (BTK) as our Clovertex Target of the Month. Nurix Therapeutics has made waves with its FDA Fast Track designation for NX-5948, a groundbreaking BTK degrader aimed at treating relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. BTK is a key enzyme in the B cell receptor signaling pathway, essential for the development and functioning of B cells. It plays a critical role in B-cell malignancies, where its abnormal activity drives the progression of diseases like chronic lymphocytic leukemia and small lymphocytic lymphoma. By targeting BTK, Nurix offers a strategic approach to stop or even reverse the growth of these cancers. What sets Nurix's platform apart is its capability to overcome mutation resistance and entirely eliminate BTK scaffolding, providing a significant advantage over traditional therapies.
The featured rendering displays the AF2 structure prediction of full-length BTK (AF2 database entry Q06187).
About Clovertex
Clovertex is an industry leader specializing in meeting the scientific IT needs of pharmaceutical companies, with a robust focus on cloud-based or on-premises cryo-EM processing. As an Advanced Tier Services Partner with Amazon Web Services (AWS), Clovertex leverages its comprehensive expertise to architect, build, automate, and manage software applications designed to meet specific research needs. Our all-encompassing solutions are meticulously tailored to streamline the complex processes associated with pharmaceutical research, underscoring our commitment to innovation, efficiency, and customer satisfaction. By integrating state-of-the-art technology with deep scientific understanding, Clovertex paves the way in optimizing the intersection of information technology and pharmaceutical development.
Useful links
1. Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL
2. Clovertex website
